Literature DB >> 25132775

Human liver stem/progenitor cells decrease serum bilirubin in hyperbilirubinemic Gunn rat.

Cédric Maerckx1, Tatiana Tondreau1, Silvia Berardis1, Jos van Pelt1, Mustapha Najimi1, Etienne Sokal1.   

Abstract

AIM: To test the ability of adult-derived human liver stem/progenitor cells (ADHLSC) from large scale cultures to conjugate bilirubin in vitro and in bilirubin conjugation deficient rat.
METHODS: ADHLSC from large scale cultures were tested for their phenotype and for their capacity to conjugate bilirubin in vitro after hepatogenic differentiation. In vivo, Gunn rats [uridine diphosphate-glucuronosyltransferase 1A1 (UGT1A1) deficient animal] were injected with ADHLSC and cryopreserved hepatocytes (positive control). Two, 4, 13 and 27 wk post-transplantation, transplanted Gunn rat bilirubin serum levels were determined by high performance liquid chromatography. Human transplanted cell engraftment was assessed 27 wk post-transplantation using immunohistochemistry and RTqPCR.
RESULTS: Large scale culture conditions do not modify ADHLSC phenotype, ADHLSC were able to specifically conjugate bilirubin. ADHLSC were intraportally injected into Gunn rats and blood UCB was measured at different times post-transplantation, infused-Gunn rats exhibited a metabolic effect 3 mo post-transplantation and maintained over a 6 mo period. ADHLSC engraftment into Gunn rat's liver was demonstrated by RTqPCR and immunohistochemistry against albumin and UGT1A1.
CONCLUSION: ADHLSC from large scale cultures are efficient in conjugating bilirubin in vitro and in restoring a deficient metabolic function (reducing bilirubin level) in hyperbilirubinemic rats.

Entities:  

Keywords:  Gunn rat; Hepatocyte; Liver stem/progenitor cells; Uridine diphosphate-glucuronosyltransferase 1A1; in vitro and in situ differentiation

Mesh:

Substances:

Year:  2014        PMID: 25132775      PMCID: PMC4130866          DOI: 10.3748/wjg.v20.i30.10553

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  35 in total

1.  Hepatocyte transplantation as a treatment for glycogen storage disease type 1a.

Authors:  Maurizio Muraca; Giorgio Gerunda; Daniele Neri; Maria-Teresa Vilei; Anna Granato; Paolo Feltracco; Muzio Meroni; Gianpiero Giron; Alberto B Burlina
Journal:  Lancet       Date:  2002-01-26       Impact factor: 79.321

2.  Congenital familial nonhemolytic jaundice with kernicterus.

Authors:  J F CRIGLER; V A NAJJAR
Journal:  Pediatrics       Date:  1952-08       Impact factor: 7.124

Review 3.  Hepatocyte transplantation.

Authors:  Ira J Fox; Jayanta Roy-Chowdhury
Journal:  J Hepatol       Date:  2004-06       Impact factor: 25.083

Review 4.  Update on liver cell transplantation.

Authors:  M Najimi; E Sokal
Journal:  J Pediatr Gastroenterol Nutr       Date:  2004-10       Impact factor: 2.839

5.  Human mesenchymal stem cells modulate allogeneic immune cell responses.

Authors:  Sudeepta Aggarwal; Mark F Pittenger
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

6.  Sustained engraftment and tissue enzyme activity after liver cell transplantation for argininosuccinate lyase deficiency.

Authors:  Xavier Stéphenne; Mustapha Najimi; Catherine Sibille; Marie-Cécile Nassogne; Françoise Smets; Etienne M Sokal
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

7.  Hepatocyte transplantation in a 4-year-old girl with peroxisomal biogenesis disease: technique, safety, and metabolic follow-up.

Authors:  Etienne M Sokal; Françoise Smets; Annick Bourgois; Lionel Van Maldergem; Jean-Paul Buts; Raymond Reding; Jean Bernard Otte; Veerle Evrard; Dominique Latinne; Marie Françoise Vincent; Anne Moser; Humberto E Soriano
Journal:  Transplantation       Date:  2003-08-27       Impact factor: 4.939

8.  Engraftment assessment in human and mouse liver tissue after sex-mismatched liver cell transplantation by real-time quantitative PCR for Y chromosome sequences.

Authors:  Ling-Jia Wang; Yong Ming Chen; David George; Francois Smets; Etienne M Sokal; Eric G Bremer; Humberto E Soriano
Journal:  Liver Transpl       Date:  2002-09       Impact factor: 5.799

9.  Normal hepatocytes correct serum bilirubin after repopulation of Gunn rat liver subjected to irradiation/partial resection.

Authors:  Chandan Guha; Bhupesh Parashar; Niloy J Deb; Madhur Garg; Giridhar R Gorla; Anupam Singh; Namita Roy-Chowdhury; Bhadrasain Vikram; Jayanta Roy-Chowdhury
Journal:  Hepatology       Date:  2002-08       Impact factor: 17.425

10.  Treatment of Crigler-Najjar type 1 disease: relevance of early liver transplantation.

Authors:  Rolf Schauer; Manfred Stangl; Thomas Lang; Andreas Zimmermann; Alexander Chouker; Alexander L Gerbes; Friedrich W Schildberg; Horst G Rau
Journal:  J Pediatr Surg       Date:  2003-08       Impact factor: 2.545

View more
  4 in total

1.  New Tools in Experimental Cellular Therapy for the Treatment of Liver Diseases.

Authors:  Jennifer R Ferrer; Attasit Chokechanachaisakul; Jason A Wertheim
Journal:  Curr Transplant Rep       Date:  2015-06-01

Review 2.  Liver-derived human mesenchymal stem cells: a novel therapeutic source for liver diseases.

Authors:  Yini Wang; Xiaopeng Yu; Ermei Chen; Lanuan Li
Journal:  Stem Cell Res Ther       Date:  2016-05-12       Impact factor: 6.832

Review 3.  Mesenchymal Stem Cells in the Adult Human Liver: Hype or Hope?

Authors:  Irina V Kholodenko; Leonid K Kurbatov; Roman V Kholodenko; Garik V Manukyan; Konstantin N Yarygin
Journal:  Cells       Date:  2019-09-22       Impact factor: 6.600

4.  Human liver stem cells express UGT1A1 and improve phenotype of immunocompromised Crigler Najjar syndrome type I mice.

Authors:  Elvira Smeralda Famulari; Victor Navarro-Tableros; Maria Beatriz Herrera Sanchez; Giulia Bortolussi; Marta Gai; Laura Conti; Lorenzo Silengo; Emanuela Tolosano; Ciro Tetta; Andrés Fernando Muro; Giovanni Camussi; Sharmila Fagoonee; Fiorella Altruda
Journal:  Sci Rep       Date:  2020-01-21       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.